Targeting HIF-1α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues

A combination of anti???CTLA-4 plus anti???PD-1/PD-L1 is the most effective cancer immunotherapy but causes high incidence of immune-related adverse events (irAEs). Here we report that targeting of HIF-1?? suppressed PD-L1 expression on tumor cells and tumor-infiltrating myeloid cells, but unexpectedly induced PD-L1 in normal tissues by an IFN-?????dependent mechanism. Targeting the HIF-1??/PD-L1 axis in tumor cells reactivated tumor-infiltrating lymphocytes and caused tumor rejection. The HIF-1?? inhibitor echinomycin potentiated the cancer immunotherapeutic effects of anti???CTLA-4 therapy, with efficacy comparable to that of anti???CTLA-4 plus anti???PD-1 antibodies. However, while anti???PD-1 exacerbated irAEs triggered by ipilimumab, echinomycin protected mice against irAEs by increasing PD-L1 levels in normal tissues. Our data suggest that targeting HIF-1?? fortifies the immune tolerance function of the PD-1/PD-L1 checkpoint in normal tissues but abrogates its immune evasion function in the tumor microenvironment to achieve safer and more effective immunotherapy.

Automated summary

This study found that targeting HIF-1α inhibition can increase the expression of PD-L1 on tumor cells and tumor-infiltrating myeloid cells, activating immune cells and leading to tumor rejection. The HIF-1α inhibitor Echinomycin not only enhances the immunotherapeutic effects of anti-CTLA-4 therapy, but also protects against immune-related adverse events by increasing PD-L1 levels in normal tissues.